ES2689103T3 - Nuevo derivado de nicotinamida o sal del mismo - Google Patents
Nuevo derivado de nicotinamida o sal del mismo Download PDFInfo
- Publication number
- ES2689103T3 ES2689103T3 ES11801034.7T ES11801034T ES2689103T3 ES 2689103 T3 ES2689103 T3 ES 2689103T3 ES 11801034 T ES11801034 T ES 11801034T ES 2689103 T3 ES2689103 T3 ES 2689103T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- substituent
- optionally
- following
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000005480 nicotinamides Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 90
- -1 C1- alkoxy 6 Chemical group 0.000 abstract 18
- 125000005843 halogen group Chemical group 0.000 abstract 16
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000003277 amino group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- 125000002252 acyl group Chemical group 0.000 abstract 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 125000005493 quinolyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000005945 imidazopyridyl group Chemical group 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 abstract 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000005936 piperidyl group Chemical group 0.000 abstract 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 abstract 1
- 125000002755 pyrazolinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Abstract
Un derivado de nicotinamida representado por la siguiente fórmula (I) o una sal del mismo:**Fórmula** en donde R1 representa un átomo de halógeno; R2 es un sustituyente representado por uno cualquiera de las siguientes fórmulas (II) a (V) y (VII):**Fórmula** en donde R10, R11, R12, R13, R16, R17, R18, R20 y R21 representan cada uno, independientemente, un átomo de hidrógeno o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, arilo, alcoxi C1-6, ariloxi, acilo, alquilsulfonilo C1-6, arilsulfonilo o heterocíclico, que tienen cada uno opcionalmente al menos un sustituyente, R14, R15, R19 y R30 representan cada uno, independientemente, un átomo de hidrógeno o un grupo alquilo C1-12 o acilo, que tiene cada uno opcionalmente al menos un sustituyente, X8 representa un átomo de oxígeno, un átomo de azufre o >=NR23 (en donde R23 representa un átomo de hidrógeno o un grupo alquilo C1-12, alquenilo C2-12, alquinilo C2-12, cicloalquilo C3-8 o alcoxi C1-6, que tienen cada uno opcionalmente al menos un sustituyente), R22 representa un grupo heterocíclico que tiene opcionalmente al menos un sustituyente, X9 y X10 representan cada uno, independientemente un átomo de oxígeno, -NR31- (en donde R31 representa un átomo de hidrógeno o un grupo alquilo C1-12, alquenilo C2-12, alquinilo C2-12, cicloalquilo C3-8, alcoxi C1-6, acilo, alcoxicarbonilo C1-6, ariloxicarbonilo u oxicarbonilo heterocíclico, que tiene cada uno opcionalmente al menos un sustituyente), o un grupo metileno (en donde uno de X9 y X10 representa un grupo metileno, y cuando m3 es 0, X10 representa un grupo metileno), m1 y m3 representan cada uno, independientemente, un número entero de 0 a 2, m2 representa un número entero de 1 o 2, en donde R20 y R21 pueden ser diferentes cada uno del otro cuando m2 es 2, n representa un número entero de 0 a 4, R16 puede ser diferente cada uno del otro cuando n es de 2 a 4, y en donde R10 y R11, R12 y R13, R17 y R18, y R20 y R21 pueden formar juntos un grupo cicloalquilo C3-8 o heterocíclico, que tienen cada uno opcionalmente al menos un sustituyente; R3 representa un grupo arilo que tiene opcionalmente al menos un sustituyente o un grupo heterocíclico que tiene opcionalmente al menos un sustituyente; y R4 y R5 representan cada uno, independientemente, un átomo de hidrógeno, un grupo alquilo C1-12, un grupo alquenilo C2-12 o un grupo alquinilo C2-12; en donde el grupo arilo es un grupo fenilo, naftilo, indanilo o indenilo; en donde el grupo heterocíclico se selecciona entre azetidinilo, pirrolidinilo, pirrolinilo, pirrolilo, piperidilo, tetrahidropiridilo, piridilo, homopiperidinilo, octahidroazocinilo, imidazolidinilo, imidazolinilo, imidazolilo, pirazolidinilo, pirazolinilo, pirazolilo, piperazinilo, pirazinilo, piridazinilo, pirimidinilo, homopiperazinilo, triazolilo, tetrazolilo, tetrahidrofuranilo, furanilo, tetrahidropiranilo, piranilo, tienilo, oxazolilo, isoxazolilo, oxadiazolilo, morfolinilo, tiazolilo, isotiazolilo, tiadiazolilo, tiomorfolinilo, 1- oxidotiomorfolinilo, 1,1-dioxido-tiomorfolinilo, indolinilo, indolilo, isoindolinilo, isoindolilo, benzoimidazolilo, indazolilo, benzotriazolilo, quinolilo, tetrahidroquinolinilo, quinolilo, tetrahidroisoquinolinilo, isoquinolinilo, quinolizinilo, cinolinilo, ftalazinilo, quinazolinilo, dihidroquinoxalinilo, quinoxalinilo, naftiridinilo, pirrolopiridilo, imidazopiridilo, indolidinilo, dihidrociclopentapiridilo, triazolopiridilo, pirazolopiridilo, piridopirazilo, purinilo, pteridinilo, quinuclidinilo, 2,3- dihidrobenzofuranilo, benzofuranilo, isobenzofuranilo, cromanilo, cromenilo, isocromanilo, 1,3-benzodioxolilo, 1,3- benzodioxanilo, 1,4-benzodioxanilo, 2,3-dihidrobenzotienilo, benzotienilo, benzoxazolilo, benzoisoxazolilo, benzoxadiazolilo, benzomorfolinilo, dihidropiranopiridilo, dihidrodioxinopiridilo, 1,3-dioxolopiridilo, dihidropiridooxazinilo, benzotiazolilo, benzoisotiazolilo, benzotiadiazolilo y tiazolopiridilo; en donde el sustituyente opcionalmente poseído por sustituyentes representados por R2 se selecciona entre el grupo sustituyente α1-2, en donde el grupo sustituyente α1-2 consiste en un átomo de halógeno; un grupo ciano; un grupo nitro; un grupo oxo; un grupo carboxilo opcionalmente protegido; un grupo hidroxilo opcionalmente protegido; un grupo amino opcionalmente protegido; un grupo alquilo C1-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo alquenilo C2-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo alquinilo C2-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo arilo que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo alcoxi C1-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo ariloxi que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1- 1; un grupo acilo que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo alquilsulfonilo C1-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo arilsulfonilo que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; un grupo heterocíclico que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß1-1; y un grupo representado por la fórmula -Q1-Q2- NR6R7 (en donde R6 y R7 representan cada uno, independientemente un átomo de hidrógeno, un grupo amino protector, un grupo alquilo C1-6 que tiene opcionalmente al menos un sustituyente, un grupo alquenilo C2-6 que tiene opcionalmente al menos un sustituyente, un grupo alquinilo C2-6 que tiene opcionalmente al menos un sustituyente, un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un sustituyente, un grupo alcoxi C1-6 que tiene opcionalmente al menos un sustituyente, un grupo arilo que tiene opcionalmente al menos un sustituyente, o un grupo heterocíclico que tiene opcionalmente al menos un sustituyente, o R6 y R7 pueden formar un grupo amino cíclico que tiene opcionalmente al menos un sustituyente, junto con el átomo de nitrógeno al que están unidos; Q1 representa -NH-, un grupo alquileno C1-6 que tiene opcionalmente al menos un sustituyente, un grupo alquenileno C2-6 que tiene opcionalmente al menos un sustituyente, un grupo alquinileno C2-6 que tiene opcionalmente al menos un sustituyente, o un enlace; Q2 representa un grupo representado por - C(>=X7)- (en donde X7 representa un átomo de oxígeno, un átomo de azufre, o un grupo representado por >=NR29 (en donde R29 representa un átomo de hidrógeno, un grupo alquilo C1-12 que tiene opcionalmente al menos un sustituyente, un grupo alquenilo C2-12 que tiene opcionalmente al menos un sustituyente, un grupo alquinilo C2-12 que tiene opcionalmente al menos un sustituyente, un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un sustituyente o un grupo alcoxi C1-6 que tiene opcionalmente al menos un sustituyente)), un grupo alquileno C1-6, o un enlace), en donde el grupo sustituyente ß1-1 consiste en un átomo de halógeno, un grupo ciano, un grupo nitro, un grupo oxo, un grupo carboxilo opcionalmente protegido, un grupo hidroxilo opcionalmente protegido, un grupo amino opcionalmente protegido, un grupo alquilo C1-6 que tiene opcionalmente al menos un átomo de halógeno, un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un átomo de halógeno, un grupo alcoxi C1-6 que tiene opcionalmente al menos un átomo de halógeno, un grupo arilo que tiene opcionalmente al menos un átomo de halógeno, y un grupo heterocíclico que tiene opcionalmente al menos un átomo de halógeno; en donde el sustituyente opcionalmente poseído por los grupos arilo o heterocíclico representado por R3 se selecciona entre el siguiente grupo sustituyente α2-2, en donde el grupo sustituyente α2-2 consiste en un átomo de halógeno; un grupo ciano; un grupo nitro; un grupo oxo; un grupo carboxilo opcionalmente protegido; un grupo hidroxilo opcionalmente protegido; un grupo amino opcionalmente protegido; un grupo alquilo C1-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo alquenilo C2-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo alquinilo C2-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo arilo que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo alcoxi C1-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo ariloxi que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2- 1; un grupo acilo que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo alquilsulfonilo C1-6 que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo arilsulfonilo que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; un grupo heterocíclico que tiene opcionalmente al menos un sustituyente seleccionado entre el siguiente grupo sustituyente ß2-1; y un grupo representado por la fórmula -Q3-Q4- NR24R25 (en donde R24 y R25 representan cada uno, independientemente un átomo de hidrógeno, un grupo amino protector, un grupo alquilo C1-6 que tiene opcionalmente al menos un sustituyente, un grupo alquenilo C2-6 que tiene opcionalmente al menos un sustituyente, un grupo alquinilo C2-6 que tiene opcionalmente al menos un sustituyente, un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un sustituyente, un grupo alcoxi C1-6 que tiene opcionalmente al menos un sustituyente, un grupo ar-alquilo C1-6 que tiene opcionalmente al menos un sustituyente, un grupo arilo que tiene opcionalmente al menos un sustituyente, un grupo heterocíclico que tiene opcionalmente al menos un sustituyente, o R24 y R25 pueden formar un grupo amino cíclico que tiene opcionalmente al menos un sustituyente, junto con el átomo de nitrógeno al que están unidos; Q3 representa -NH-, un grupo alquileno C1-6 que tiene opcionalmente al menos un sustituyente, un grupo alquenileno C2-6 que tiene opcionalmente al menos un sustituyente, un grupo alquinileno C2-6 que tiene opcionalmente al menos un sustituyente o un enlace; y Q4 representa -C(>=O)-, un grupo alquileno C1-6 o un enlace); y en donde el grupo sustituyente ß2-1 consiste en un átomo de halógeno, un grupo ciano, un grupo nitro, un grupo oxo, un grupo carboxilo opcionalmente protegido, un grupo hidroxilo opcionalmente protegido, un grupo amino opcionalmente protegido, un grupo alquilo C1-6 que tiene opcionalmente al menos un átomo de halógeno, un grupo cicloalquilo C3-8 que tiene opcionalmente al menos un átomo de halógeno, un grupo alcoxi C1-6 que tiene opcionalmente al menos un átomo de halógeno, un grupo ar-alquilo C1-6 que tiene opcionalmente al menos un átomo de halógeno, un grupo arilo que tiene opcionalmente al menos un átomo de halógeno, y un grupo heterocíclico que tiene opcionalmente al menos un átomo de halógeno.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010150495 | 2010-06-30 | ||
JP2010150495 | 2010-06-30 | ||
PCT/JP2011/065530 WO2012002577A1 (ja) | 2010-06-30 | 2011-06-30 | 新規なニコチンアミド誘導体またはその塩 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2689103T3 true ES2689103T3 (es) | 2018-11-08 |
Family
ID=45402271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11801034.7T Active ES2689103T3 (es) | 2010-06-30 | 2011-06-30 | Nuevo derivado de nicotinamida o sal del mismo |
Country Status (21)
Country | Link |
---|---|
US (1) | US8895585B2 (es) |
EP (1) | EP2589592B1 (es) |
JP (1) | JP5744021B2 (es) |
KR (1) | KR101789129B1 (es) |
CN (1) | CN102958918B (es) |
AU (1) | AU2011272198B2 (es) |
BR (1) | BR112012033770A2 (es) |
CA (1) | CA2803842C (es) |
DK (1) | DK2589592T3 (es) |
ES (1) | ES2689103T3 (es) |
HK (1) | HK1181762A1 (es) |
IL (1) | IL223818B (es) |
MX (1) | MX2012015023A (es) |
MY (1) | MY177250A (es) |
NZ (1) | NZ603837A (es) |
PL (1) | PL2589592T3 (es) |
RU (1) | RU2560163C2 (es) |
SG (1) | SG186877A1 (es) |
TW (1) | TWI561512B (es) |
WO (1) | WO2012002577A1 (es) |
ZA (1) | ZA201300095B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846928B2 (en) | 2010-11-01 | 2014-09-30 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
US9309212B2 (en) | 2011-05-24 | 2016-04-12 | The Wistar Institute | Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1 |
JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
PL2799431T3 (pl) * | 2011-12-28 | 2018-07-31 | Fujifilm Corporation | Nowa pochodna nikotynamidu lub jej sól |
US20130310387A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
US9550750B2 (en) * | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する1,2,4−トリアジン−6−カルボキサミド誘導体 |
AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
US10030004B2 (en) * | 2014-01-01 | 2018-07-24 | Medivation Technologies Llc | Compounds and methods of use |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
JP6472419B2 (ja) | 2015-09-30 | 2019-02-20 | 富士フイルム株式会社 | 芳香族化合物の製造方法 |
SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
US10934285B2 (en) | 2016-06-14 | 2021-03-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
KR102524773B1 (ko) | 2017-01-26 | 2023-04-21 | 싸이클라셀 리미티드 | 퓨린 유도체의 제조 방법 |
KR102296703B1 (ko) | 2017-03-20 | 2021-09-01 | 포르마 세라퓨틱스 인크. | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 |
CN116370448A (zh) | 2017-04-26 | 2023-07-04 | 纳维托制药有限公司 | Sestrin-gator2相互作用的调节剂及其用途 |
US11168082B2 (en) * | 2017-05-15 | 2021-11-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors |
WO2018228475A1 (zh) * | 2017-06-14 | 2018-12-20 | 正大天晴药业集团股份有限公司 | Syk抑制剂及其使用方法 |
RS63623B1 (sr) | 2017-12-13 | 2022-10-31 | Lupin Ltd | Supstituisana biciklična heterociklična jedinjenja kao inhibitori prmt5 |
BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
JP7292394B2 (ja) * | 2018-12-21 | 2023-06-16 | サルティゴ・ゲーエムベーハー | 2-アルコキシ-4-アミノ-5-メチル-ピリジン及び/又は2-アルコキシ-4-アルキルアミノ-5-メチル-ピリジンを調製するためのプロセス |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN114026094B (zh) | 2019-06-10 | 2024-06-25 | 印度鲁宾有限公司 | Prmt5抑制剂 |
CN112538072B (zh) * | 2019-09-21 | 2024-02-06 | 齐鲁制药有限公司 | 氨基嘧啶类egfr抑制剂 |
MX2022005215A (es) | 2019-11-01 | 2022-06-08 | Navitor Pharm Inc | Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1). |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR121149A1 (es) | 2020-01-30 | 2022-04-20 | Fmc Corp | Compuestos piridina para controlar plagas de invertebrados |
TW202317528A (zh) | 2021-06-24 | 2023-05-01 | 美商富曼西公司 | 用於防治無脊椎有害生物的唑類化合物 |
CN114230490A (zh) * | 2021-12-28 | 2022-03-25 | 乐威医药(江苏)股份有限公司 | 一种n-烷基化双胺的制备方法 |
EP4370506A1 (en) | 2021-12-30 | 2024-05-22 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133253A (en) | 1996-12-10 | 2000-10-17 | Abbott Laboratories | 3-Pyridyl enantiomers and their use as analgesics |
PT1184376E (pt) | 1999-06-09 | 2005-04-29 | Yamanouchi Pharma Co Ltd | Novos derivados heterociclicos de carboxamida |
DE60135854D1 (de) | 2000-08-04 | 2008-10-30 | Warner Lambert Co | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-one |
EP2033952B1 (en) | 2001-03-01 | 2012-08-29 | Shionogi&Co., Ltd. | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity |
JP2005503416A (ja) | 2001-09-17 | 2005-02-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 6−o−カルバメート−11,12−ラクト−ケトライド抗菌剤 |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US20060079522A1 (en) | 2004-10-08 | 2006-04-13 | Marzabadi Mohammad R | Amino substituted aryloxybenzylpiperidine derivatives |
GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
BRPI0606793A8 (pt) | 2005-02-04 | 2018-03-13 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica |
RU2415852C2 (ru) * | 2005-02-04 | 2011-04-10 | Астразенека Аб | Производные пиразолиламинопиридина, пригодные в качестве ингибиторов киназы |
GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | 2−アミノキナゾリン誘導体 |
EP1896461A2 (en) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
CA2642211C (en) | 2006-02-17 | 2012-01-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
BRPI0710487A2 (pt) | 2006-04-12 | 2012-06-05 | Merck & Co Inc | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitácel do mesmo e, método para tratar ou controlar a epilepsia e a dor e para o tratamento ou prevenção de um distúrbio do sono em um paciente. |
JP2008013499A (ja) | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | 5−シアノニコチンアミド誘導体 |
EP2069851A4 (en) | 2006-09-14 | 2010-02-24 | Tessera Tech Hungary Kft | IMAGING SYSTEM WITH ASSOUPLY ASSEMBLED TOLERANCES AND ASSOCIATED METHODS |
WO2008049855A2 (en) | 2006-10-27 | 2008-05-02 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
WO2008102870A1 (ja) | 2007-02-23 | 2008-08-28 | Eisai R & D Management Co., Ltd. | Hgfr遺伝子増幅細胞株に優れた細胞増殖阻害効果および抗腫瘍効果を示すピリジン誘導体またはピリミジン誘導体 |
TW200904421A (en) * | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
WO2009018344A1 (en) | 2007-07-30 | 2009-02-05 | Regents Of The University Of Minnesota | Anticancer agents |
WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
US8022209B2 (en) | 2007-09-12 | 2011-09-20 | Janssen Pharmaceutica Nv | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor |
AR068509A1 (es) * | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2009090548A2 (en) | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
JP5705720B2 (ja) | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Sykまたはjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド |
SG2014015085A (en) | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
AU2009259494A1 (en) | 2008-06-16 | 2009-12-23 | F. Hoffmann-La Roche Ag | Heteroaromatic monoamides as orexinin receptor antagonists |
CN102112942A (zh) * | 2008-07-31 | 2011-06-29 | 圣纳普斯有限责任公司 | 基于计算机的算盘训练系统 |
JP2012515148A (ja) | 2009-01-13 | 2012-07-05 | グラクソ グループ リミテッド | Sykキナーゼ阻害剤としてのピリミジンカルボキサミド誘導体 |
CN102458402B (zh) * | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
US8846928B2 (en) * | 2010-11-01 | 2014-09-30 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
-
2011
- 2011-06-30 AU AU2011272198A patent/AU2011272198B2/en not_active Ceased
- 2011-06-30 JP JP2012522731A patent/JP5744021B2/ja not_active Expired - Fee Related
- 2011-06-30 KR KR1020137001065A patent/KR101789129B1/ko active IP Right Grant
- 2011-06-30 DK DK11801034.7T patent/DK2589592T3/en active
- 2011-06-30 WO PCT/JP2011/065530 patent/WO2012002577A1/ja active Application Filing
- 2011-06-30 PL PL11801034T patent/PL2589592T3/pl unknown
- 2011-06-30 MY MYPI2012005634A patent/MY177250A/en unknown
- 2011-06-30 SG SG2012096632A patent/SG186877A1/en unknown
- 2011-06-30 CA CA2803842A patent/CA2803842C/en not_active Expired - Fee Related
- 2011-06-30 BR BR112012033770A patent/BR112012033770A2/pt not_active Application Discontinuation
- 2011-06-30 EP EP11801034.7A patent/EP2589592B1/en active Active
- 2011-06-30 TW TW100123081A patent/TWI561512B/zh not_active IP Right Cessation
- 2011-06-30 ES ES11801034.7T patent/ES2689103T3/es active Active
- 2011-06-30 MX MX2012015023A patent/MX2012015023A/es active IP Right Grant
- 2011-06-30 RU RU2013103792/04A patent/RU2560163C2/ru active
- 2011-06-30 NZ NZ603837A patent/NZ603837A/en not_active IP Right Cessation
- 2011-06-30 CN CN201180031719.6A patent/CN102958918B/zh not_active Expired - Fee Related
-
2012
- 2012-12-24 IL IL223818A patent/IL223818B/en active IP Right Grant
- 2012-12-28 US US13/730,000 patent/US8895585B2/en active Active
-
2013
- 2013-01-04 ZA ZA2013/00095A patent/ZA201300095B/en unknown
- 2013-08-01 HK HK13109009.5A patent/HK1181762A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2011272198A1 (en) | 2013-02-07 |
EP2589592A4 (en) | 2014-01-01 |
PL2589592T3 (pl) | 2019-03-29 |
BR112012033770A2 (pt) | 2016-11-22 |
MX2012015023A (es) | 2013-04-03 |
AU2011272198B2 (en) | 2016-09-22 |
CA2803842C (en) | 2020-01-07 |
SG186877A1 (en) | 2013-02-28 |
RU2560163C2 (ru) | 2015-08-20 |
IL223818B (en) | 2019-09-26 |
MY177250A (en) | 2020-09-10 |
EP2589592B1 (en) | 2018-08-22 |
US20130116430A1 (en) | 2013-05-09 |
EP2589592A1 (en) | 2013-05-08 |
TWI561512B (en) | 2016-12-11 |
CN102958918B (zh) | 2015-12-09 |
TW201215602A (en) | 2012-04-16 |
CN102958918A (zh) | 2013-03-06 |
US8895585B2 (en) | 2014-11-25 |
JP5744021B2 (ja) | 2015-07-01 |
CA2803842A1 (en) | 2012-01-05 |
HK1181762A1 (zh) | 2013-11-15 |
WO2012002577A1 (ja) | 2012-01-05 |
KR101789129B1 (ko) | 2017-11-20 |
NZ603837A (en) | 2014-01-31 |
JPWO2012002577A1 (ja) | 2013-08-29 |
RU2013103792A (ru) | 2014-08-10 |
ZA201300095B (en) | 2014-03-26 |
DK2589592T3 (en) | 2018-11-26 |
KR20130088130A (ko) | 2013-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2689103T3 (es) | Nuevo derivado de nicotinamida o sal del mismo | |
AR076562A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
FI3381896T3 (fi) | Bifenyyliyhdiste tai sen suola | |
AR097744A1 (es) | Proceso para producir derivado de diazabiciclooctano y su intermediario | |
ES2721627T3 (es) | Nuevo derivado de amina o sal del mismo como inhibidores de TNF alfa | |
ES2552549T3 (es) | Compuestos de carboxamida para el tratamiento de trastornos metabólicos | |
RS53682B1 (en) | PIRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASE | |
CO4950619A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
AR076563A1 (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica | |
AR049346A1 (es) | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas | |
BRPI0506918A (pt) | derivados de tipo ariloxialquilcarbamatos, sua preparação e sua aplicação terapêutica | |
WO2003090539A8 (de) | 3-heteroarylsubstituierte 5 methyloxymethyl-isoxazoline als herbizide | |
AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
GEP20156267B (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | |
AR075247A1 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica | |
AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
AR047818A1 (es) | Derivados de piperidinilalquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
AR044178A1 (es) | Derivados de piperidinil- y piperazinil-alquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
ES2563317T3 (es) | Pirrolidinonas como inhibidores de MetAP-2 | |
AR064517A1 (es) | Pirimidinionas biciclicas y sus usos | |
AR076561A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
ES2182531T3 (es) | Azoles solubles en agua como antifungicos de amplio espectro. | |
RS54382B1 (en) | ANTI-BACTERIAL DERIVATIVES OF HINOLINE | |
AR094123A1 (es) | Compuesto triciclicos | |
AR064153A1 (es) | Derivados de quinolina antibacterianos. procesos de obtencion y composiciones farmaceuticas. |